Published in Health and Medicine Week, October 10th, 2005
Sankyo Company, Limited and Daiichi Pharmaceutical Co., Ltd. will establish and newly list the joint holding company Daiichi Sankyo Company, Limited under which both companies will become its wholly owned subsidiaries, and in line with this, we will be delisted.
Current president and representative director, Takashi Shoda, will take on the management of the new Daiichi Sankyo Group as the representative director, president and CEO of Daiichi Sankyo company, Limited and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.